SOURCE: Michelex


February 25, 2011 09:45 ET

Michelex (PINKSHEETS: MLXO) Announces First Shipment of Pharmaceutical Products From Massena Facility

NEW YORK, NY--(Marketwire - February 25, 2011) - Michelex Corporation (PINKSHEETS: MLXO) ("Michelex") President Mr. Albert Laclé is pleased to announce the shipment of the first batch of products from Pristine Pharma Corporation's newly constructed manufacturing facility in Massena, NY, on Feb 23, 2011, to an export distributor for Caribbean countries.

Mr. Venkat Kakani, CEO of Pristine, is excited about near-term plans to expand Pristine's North American territory beyond the Caribbean by distributing, for the first time, its products to Central America. 

In further news, the FDA's Center for Drug Evaluation and Research ("CDER-FDA") issued labeler code 76044 to Pristine on Feb 22, 2011. This labeler code is the prefix to the New Drug Code Number (NDC#) for each drug manufactured at Pristine's facility. NDC numbers appear on drug labels and packages identifying the manufacturer of the drug product.


Michelex Corporation, founded in 1999, is currently comprised of subsidiaries with a diversified portfolio of businesses in the areas of financial services and pharmaceutical drug manufacturing and distribution.


Pristine Pharma Corporation was founded in 2009 and became a wholly owned subsidiary of the Michelex Corp. in July 2010. Pristine owns pharmaceutical manufacturing assets for the production and packaging of both liquid and solid dose medicines. Pristine supplies National Brand Equivalents of Over The Counter medicines to national and international wholesalers both in private-label and its own brand, "NUMED," and to retailers in store brands.

More information about Michelex and Pristine is available at the following:

Safe Harbor:
This release may contain forward-looking statements within the meaning of the Private Securities Litigation reform Act of 1995. These statements and the matters discussed in this news release are forward-looking statements that involve a number of important risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements, including, but not limited to, the extremely limited operating history, the performance of the subsidiaries, as well as other economic, competitive and technological factors involving the subsidiaries' operations, markets, services, products and prices., uncertainties related to the company's access to additional capital, the ability of the subsidiaries to enter into contracts with new customers, and dependency on key management.

Contact Information

  • For further information, contact
    Email Contact
    Michelex Corporation
    204 Haledon Ave
    Prospect Park, NJ 07508